AAT Augmentation denied for missing prior authorization by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for aat augmentation are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Requires Prior Authorization for AAT Augmentation

Alpha-1 antitrypsin augmentation therapy is an expensive specialty infusion, and Blue Cross Blue Shield plans almost universally require prior authorization (PA) before the therapy begins. A denial labeled "prior-auth-required" typically means the service was administered — or the claim was submitted — without an approved PA on file. It can also mean a PA was requested but denied for failure to supply required documentation before the deadline.

This is a process denial, not a clinical one, but it is still fully appealable and the underlying clinical case is strong when the diagnosis is confirmed.

## Why This Is Appealable

Under ACA §2719 and ERISA §503, all adverse benefit determinations — including procedural denials — are subject to internal appeal and, for non-grandfathered plans, independent external review. If the PA was never submitted, the appeal should explain the circumstances (e.g., urgent clinical need, administrative error) and include a retroactive PA request with full supporting documentation. If the PA was submitted but denied, the appeal should address the specific deficiency cited in the denial. Request expedited review if the therapy is urgently needed — decisions are required within 72 hours.

## Documentation to Gather

• Completed PA request form: Obtain BCBS's current PA request form for specialty infusion/biologics and complete it in full with the prescribing physician's signature.
• Diagnosis documentation: Laboratory confirmation of AAT deficiency (phenotype/genotype), pulmonary function test results, and clinical notes establishing active lung disease.
• Medical-necessity letter: A detailed letter from the treating physician explaining the clinical basis for AAT augmentation, referencing the patient's chart data.
• Prescribing label: Attach the FDA-approved prescribing information confirming the on-label indication.
• Timeline documentation: If the therapy was administered without PA due to urgent clinical circumstances, document the clinical urgency in the physician's letter.

## Criteria-Mapping Structure

BCBS's PA criteria for AAT augmentation are published in its clinical policy bulletins (available on the BCBS member portal or by calling provider services). List each PA criterion in a left column. In the right column, cite the specific record, test result, or note that satisfies it. Attach each supporting record as a numbered exhibit.

## Timeline

1. For retroactive PA / appeal: file within 180 days of the denial notice. 2. Standard pre-service PA appeal: BCBS must respond within 15 business days. 3. Expedited appeal for urgent ongoing treatment: 72-hour decision required. 4. After final internal denial: request external review within 4 months.